A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.
BioXcel stock craters after disclosure of investigator’s falsified safety report in Alzheimer’s study
BioXcel touted data Thursday morning claiming that Igalmi, its drug for agitation episodes, succeeded in a pivotal trial with Alzheimer’s patients, reducing a composite of